Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
-
Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
-
Sanofi: Net sales up 10.1% and Business net income(1) up 4.1% at CER(2)
-
Sanofi Video Q&A: CFO Jérôme Contamine Comments on Q3 2011 Results
-
ImmunoGen, Inc. Reports First Quarter Fiscal Year 2012 Financial Results and Provides Quarterly Update
-
Regeneron Reports Third Quarter 2011 Financial and Operating Results
-
Alemtuzumab (Lemtrada™*) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study
-
Canaccord Genuity Morning Coffee on Merck & Co. (MRK) and Sanofi-Aventis (SNY): So Long, Farewell, Au Revoir
-
Top 10 News Items 2/14-2/18: NYSE Euronext/Deutsche Boerse Announces Definitive Agreement, Sanofi, Genzyme Finally Approve Deal, Stocks Continue Higher, Up 28% Since Sept.
-
Canaccord Genuity Morning Coffee on Sanofi-Aventis (SNY) and Genzyme (GENZ): An Extra $5 Will Help The Medicine Go Down
-
Novo Nordisk (NVO) Still Poised to Gain Despite Strong 2010 - Barron's
-
Sanofi-aventis (SNY) Seeks Clarification from Genzyme (GENZ) Over Potential Board Actions
-
Q3 Preview: Merck (MRK) Trading Strong Into Earnings, Looks to Nearly Double-Up Revs Y/Y (PFE, GSK, SNY)
-
sanofi-aventis (SNY) Expands Presence in China with $520.6M Acquisition of BMP Sunstone (BJGP)
-
Highlights From AAPL's Q4 Conference Call: Set New All-Time Records for Mac, iPhone and iPad Sales
